TSHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TSHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Taysha Gene Therapies's enterprise value is $362.27 Mil. Taysha Gene Therapies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-105.20 Mil. Therefore, Taysha Gene Therapies's EV-to-EBITDA for today is -3.44.
The historical rank and industry rank for Taysha Gene Therapies's EV-to-EBITDA or its related term are showing as below:
During the past 5 years, the highest EV-to-EBITDA of Taysha Gene Therapies was -0.07. The lowest was -4.99. And the median was -0.57.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-10), Taysha Gene Therapies's stock price is $2.53. Taysha Gene Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.335. Therefore, Taysha Gene Therapies's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Taysha Gene Therapies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-EBITDA | - | -12.52 | -2.10 | -0.71 | -2.36 |
Taysha Gene Therapies Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -0.71 | -0.37 | -0.49 | -2.34 | -2.36 |
For the Biotechnology subindustry, Taysha Gene Therapies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's EV-to-EBITDA falls into.
Taysha Gene Therapies's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 362.270 | / | -105.197 | |
= | -3.44 |
Taysha Gene Therapies's current Enterprise Value is $362.27 Mil.
Taysha Gene Therapies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-105.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (NAS:TSHA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Taysha Gene Therapies's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 2.53 | / | -1.335 | |
= | At Loss |
Taysha Gene Therapies's share price for today is $2.53.
Taysha Gene Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.335.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Taysha Gene Therapies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Alison S Long | director | KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Kamran Alam | officer: Chief Financial Officer | 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118 |
Sean P. Nolan | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Phillip B. Donenberg | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Session R.a. Ii | 10 percent owner | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Sukumar Nagendran | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Astellas Pharma Inc. | 10 percent owner | 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411 |
Audentes Therapeutics, Inc. | 10 percent owner | 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108 |
Suyash Prasad | officer: CMO and Head of R&D | C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104 |
Laura Sepp-lorenzino | director | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
Kathleen Reape | director | C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235 |
From GuruFocus
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 11-07-2023
By sperokesalga sperokesalga • 06-05-2023
By Value_Insider Value_Insider • 10-25-2022
By Marketwired • 09-26-2023
By PurpleRose PurpleRose • 08-09-2022
By Value_Insider Value_Insider • 10-25-2022
By Value_Insider Value_Insider • 11-02-2022
By GuruFocus Research • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.